drugset / Trial / NCT06834035
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
Phase 1/2
Recruiting
8 enrolled
M. Peter Marinkovich
Epidermolysis Bullosa Research Partnership · collab
NaSingle-groupOpen-labelTreatment
Summary
The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound healing and affects the levels of C7 and HSV-1 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 and HSV-1 antibodies could improve quality of life.
Timeline
- Start
- 2025-08-04
- Primary completion
- 2027-03
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Immunoglobulin G | Protein / enzyme biologic | — | Intravenous |